CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,536,830 | -2.9% | 24,550 | -29.6% | 1.11% | -8.9% |
| Q3 2023 | $1,583,203 | -18.0% | 34,880 | +1.5% | 1.22% | -3.9% |
| Q2 2023 | $1,929,700 | +30.9% | 34,373 | +5.5% | 1.27% | +22.6% |
| Q1 2023 | $1,473,729 | +18.3% | 32,583 | +6.3% | 1.03% | -0.2% |
| Q4 2022 | $1,246,000 | -30.6% | 30,646 | +11.6% | 1.04% | -31.9% |
| Q3 2022 | $1,795,000 | -87.1% | 27,466 | -88.0% | 1.52% | -52.3% |
| Q2 2022 | $13,873,000 | +765.4% | 228,286 | +794.1% | 3.19% | +194.7% |
| Q1 2022 | $1,603,000 | +23.3% | 25,533 | +48.8% | 1.08% | +23.1% |
| Q4 2021 | $1,300,000 | -22.2% | 17,159 | +15.0% | 0.88% | -23.9% |
| Q3 2021 | $1,670,000 | -18.8% | 14,922 | +17.4% | 1.15% | -17.6% |
| Q2 2021 | $2,057,000 | +148.4% | 12,708 | +87.0% | 1.40% | +70.9% |
| Q1 2021 | $828,000 | -14.9% | 6,794 | +7.0% | 0.82% | -30.4% |
| Q4 2020 | $973,000 | – | 6,352 | – | 1.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |